BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33987249)

  • 1. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
    Zhang J; An L; Zhou X; Shi R; Wang H
    Ann Transl Med; 2021 Apr; 9(7):551. PubMed ID: 33987249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
    Lai J; Xu T; Yang H
    BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 8. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis.
    Yan J; Wu X; Yu J; Zhu Y; Cang S
    Front Oncol; 2020; 10():570654. PubMed ID: 33240814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
    Zhang C; Shen L; Qi F; Wang J; Luo J
    J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.